Literature DB >> 20586723

Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

F Wang1, P Jiao, M Qi, M Frezza, Q P Dou, B Yan.   

Abstract

Copper is an essential element for multiple biological processes. Its concentration is elevated to a very high level in cancer tissues for promoting cancer development through processes such as angiogenesis. Organic chelators of copper can passively reduce cellular copper and serve the role as inhibitors of angiogenesis. However, they can also actively attack cellular targets such as proteasome, which plays a critical role in cancer development and survival. The discovery of such molecules initially relied on a step by step synthesis followed by biological assays. Today high-throughput chemistry and high-throughput screening have significantly expedited the copper-binding molecules discovery to turn "cancer-promoting" copper into anti-cancer agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586723      PMCID: PMC3786439          DOI: 10.2174/092986710791859315

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  117 in total

Review 1.  Ubiquitin-mediated proteolysis: biological regulation via destruction.

Authors:  A Ciechanover; A Orian; A L Schwartz
Journal:  Bioessays       Date:  2000-05       Impact factor: 4.345

Review 2.  The 26S proteasome: a molecular machine designed for controlled proteolysis.

Authors:  D Voges; P Zwickl; W Baumeister
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

3.  Wilson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

4.  Evaluation of copper chelation agents as anti-angiogenic therapy.

Authors:  Kevin Camphausen; Mary Sproull; Steve Tantama; Sandeep Sankineni; Tamalee Scott; Cynthia Ménard; C Norman Coleman; Martin W Brechbiel
Journal:  Bioorg Med Chem       Date:  2003-09-15       Impact factor: 3.641

5.  The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.

Authors:  J Yoshii; H Yoshiji; S Kuriyama; Y Ikenaka; R Noguchi; H Okuda; H Tsujinoue; T Nakatani; H Kishida; D Nakae; D E Gomez; M S De Lorenzo; A M Tejera; H Fukui
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

6.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

7.  Pharmacokinetics and distribution of clioquinol in golden hamsters.

Authors:  Gianpietro Bondiolotti; Mariaelvina Sala; Claudia Pollera; Marco Gervasoni; Maria Puricelli; Wilma Ponti; Silvio R Bareggi
Journal:  J Pharm Pharmacol       Date:  2007-03       Impact factor: 3.765

8.  Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.

Authors:  Shreelekha Adsule; Vivek Barve; Di Chen; Fakhara Ahmed; Q Ping Dou; Subhash Padhye; Fazlul H Sarkar
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

Review 9.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.

Authors:  Michele De Palma; Craig Murdoch; Mary Anna Venneri; Luigi Naldini; Claire E Lewis
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more
  20 in total

1.  Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.

Authors:  Mohammad A Shahshahan; Maureen N Beckley; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2011-08-23       Impact factor: 6.166

2.  Copper(ii) l/d-valine-(1,10-phen) complexes target human telomeric G-quadruplex motifs and promote site-specific DNA cleavage and cellular cytotoxicity.

Authors:  Farukh Arjmand; Surbhi Sharma; Sabiha Parveen; Loic Toupet; Zhen Yu; James Allan Cowan
Journal:  Dalton Trans       Date:  2020-07-21       Impact factor: 4.390

Review 3.  Porphyrins as ligands for 64copper: background and trends.

Authors:  Edgar Aguilar-Ortíz; Amir R Jalilian; Miguel A Ávila-Rodríguez
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

4.  Site-specific radical formation in DNA induced by Cu(II)-H₂O₂ oxidizing system, using ESR, immuno-spin trapping, LC-MS, and MS/MS.

Authors:  Suchandra Bhattacharjee; Leesa J Deterding; Saurabh Chatterjee; Jinjie Jiang; Marilyn Ehrenshaft; Olivier Lardinois; Dario C Ramirez; Kenneth B Tomer; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2011-03-05       Impact factor: 7.376

5.  Cancer cell-selective killing polymer/copper combination.

Authors:  Huacheng He; Diego Altomare; Ufuk Ozer; Hanwen Xu; Kim Creek; Hexin Chen; Peisheng Xu
Journal:  Biomater Sci       Date:  2016-01       Impact factor: 6.843

6.  Detection and imaging of the free radical DNA in cells--site-specific radical formation induced by Fenton chemistry and its repair in cellular DNA as seen by electron spin resonance, immuno-spin trapping and confocal microscopy.

Authors:  Suchandra Bhattacharjee; Saurabh Chatterjee; Jinjie Jiang; Birandra Kumar Sinha; Ronald P Mason
Journal:  Nucleic Acids Res       Date:  2012-03-02       Impact factor: 16.971

7.  Downregulation of oncogenic RAS and c-Myc expression in MOLT-4 leukaemia cells by a salicylaldehyde semicarbazone copper(II) complex.

Authors:  Yan-Yih Goh; Yaw-Kai Yan; Nguan Soon Tan; Su-Ann Goh; Shang Li; You-Chuan Teoh; Peter P F Lee
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

8.  Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.

Authors:  Yi Li; Li-Hui Wang; Hao-Tian Zhang; Ya-Ting Wang; Shuai Liu; Wen-Long Zhou; Xiang-Zhong Yuan; Tian-Yang Li; Chun-Fu Wu; Jing-Yu Yang
Journal:  J Cell Mol Med       Date:  2017-11-17       Impact factor: 5.310

9.  Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Authors:  Mohamed Wehbe; Cody Lo; Ada W Y Leung; Wieslawa H Dragowska; Gemma M Ryan; Marcel B Bally
Journal:  Invest New Drugs       Date:  2017-07-21       Impact factor: 3.850

10.  Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.

Authors:  Avani Vyas; Umamaheswar Duvvuri; Kirill Kiselyov
Journal:  Biochem J       Date:  2019-12-19       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.